| ||||
| Public Act 102-1073 | ||||
| ||||
| ||||
AN ACT concerning regulation.
| ||||
Be it enacted by the People of the State of Illinois,
| ||||
represented in the General Assembly:
| ||||
Section 5. The Illinois Insurance Code is amended by | ||||
changing Section 356u as follows:
| ||||
(215 ILCS 5/356u)
| ||||
Sec. 356u. Pap tests and prostate cancer screenings | ||||
prostate-specific antigen tests.
| ||||
(a) A group policy of accident and health insurance that | ||||
provides coverage
for hospital or medical treatment or | ||||
services for illness on an
expense-incurred basis and is | ||||
amended, delivered, issued, or renewed after January 1, 2024 | ||||
the
effective date of this amendatory Act of 1997 shall | ||||
provide coverage, without imposing a deductible, coinsurance, | ||||
copayment, or any other cost-sharing requirement, for all of
| ||||
the
following:
| ||||
(1) An annual cervical smear or Pap smear test for | ||||
female insureds.
| ||||
(2) An annual prostate cancer screening digital rectal | ||||
examination and a prostate-specific
antigen test, for male | ||||
insureds upon the recommendation of a physician licensed
| ||||
to practice medicine in all its branches for:
| ||||
(A) asymptomatic men age 50 and over;
| ||||
(B) African-American men age 40 and over; and
| ||
(C) men age 40 and over with a family history of | ||
prostate cancer.
| ||
(3) Surveillance tests for ovarian cancer for female | ||
insureds who are at risk for ovarian cancer. | ||
(b) This Section shall not apply to agreements, contracts, | ||
or policies that
provide coverage for a specified disease or | ||
other limited benefit coverage.
| ||
(c) This Section does not apply to coverage of prostate | ||
cancer screenings to the extent such coverage would disqualify | ||
a high-deductible health plan from eligibility for a health | ||
savings account pursuant to Section 223 of the Internal | ||
Revenue Code. | ||
(d) (c) For the purposes of this Section: | ||
"At risk for ovarian cancer" means: | ||
(1) having a family history (i) with one or more | ||
first-degree relatives with ovarian cancer, (ii) of | ||
clusters of women relatives with breast cancer, or (iii) | ||
of nonpolyposis colorectal cancer; or | ||
(2) testing positive for BRCA1 or BRCA2 mutations. | ||
"Prostate cancer screening" means medically viable methods | ||
for the detection and diagnosis of prostate cancer, including | ||
a digital rectal exam and the prostate-specific antigen test | ||
and associated laboratory work. "Prostate cancer screening" | ||
includes medically necessary subsequent follow-up testing as | ||
directed by a health care provider, including, but not limited | ||
to: | ||
(1) urinary analysis; | ||
(2) serum biomarkers; and | ||
(3) medical imaging, including, but not limited to, | ||
magnetic resonance imaging. | ||
"Surveillance tests for ovarian cancer" means annual | ||
screening using (i) CA-125 serum tumor marker testing, (ii) | ||
transvaginal ultrasound, (iii) pelvic examination.
| ||
(Source: P.A. 94-122, eff. 1-1-06.)
| ||